HSBC Downgrades Illumina (NASDAQ:ILMN) to Hold

Illumina (NASDAQ:ILMN) was downgraded by equities research analysts at HSBC from a “buy” rating to a “hold” rating in a report issued on Friday, Marketbeat.com reports. They presently have a $100.00 target price on the life sciences company’s stock. HSBC’s target price indicates a potential upside of 12.69% from the stock’s previous close.

Several other research firms have also recently commented on ILMN. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price target for the company from $190.00 to $165.00 in a report on Wednesday, December 11th. Morgan Stanley lowered their price target on shares of Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. UBS Group boosted their price target on shares of Illumina from $133.00 to $145.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. boosted their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Finally, Canaccord Genuity Group lowered their price target on shares of Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $155.45.

Illumina Trading Down 0.3 %

NASDAQ ILMN opened at $88.74 on Friday. Illumina has a twelve month low of $87.50 and a twelve month high of $156.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77. The stock has a market cap of $14.06 billion, a price-to-earnings ratio of -11.55, a PEG ratio of 1.60 and a beta of 1.10. The firm’s 50 day moving average price is $123.38 and its two-hundred day moving average price is $133.05.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts anticipate that Illumina will post 4.51 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ILMN. Versant Capital Management Inc lifted its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock worth $32,000 after acquiring an additional 146 shares during the last quarter. Golden State Wealth Management LLC acquired a new position in Illumina during the 4th quarter worth $32,000. Fourth Dimension Wealth LLC acquired a new position in Illumina during the 4th quarter worth $40,000. Assetmark Inc. lifted its position in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company’s stock worth $44,000 after acquiring an additional 296 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich acquired a new position in Illumina during the 4th quarter worth $45,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.